VRDN

Viridian Therapeutics Inc

VRDN, USA

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

https://www.viridiantherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VRDN
stock
VRDN

10% holder buying at Viridian Metals (VRDN) The Globe and Mail

Read more →
VRDN
stock
VRDN

Understanding Momentum Shifts in (VRDN) news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$39.8333

Analyst Picks

Strong Buy

9

Buy

5

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.25

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-6.88 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.99 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-120.08 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.15

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 113.53% of the total shares of Viridian Therapeutics Inc

1.

FMR Inc

(14.9871%)

since

2025/06/30

2.

BlackRock Inc

(6.7608%)

since

2025/06/30

3.

Deep Track Capital, LP

(6.5887%)

since

2025/06/30

4.

COMMODORE CAPITAL LP

(5.9697%)

since

2025/06/30

5.

Vanguard Group Inc

(5.5209%)

since

2025/06/30

6.

Kynam Capital Management, LP

(5.4222%)

since

2025/06/30

7.

VR Adviser, LLC

(4.7546%)

since

2025/06/30

8.

Fairmount Funds Management LLC

(4.2369%)

since

2025/06/30

9.

T. Rowe Price Associates, Inc.

(3.5454%)

since

2025/06/30

10.

TANG CAPITAL MANAGEMENT LLC

(3.4813%)

since

2025/06/30

11.

Paradigm Biocapital Advisors LP

(3.3572%)

since

2025/06/30

12.

Fidelity Select Health Care

(3.2832%)

since

2025/07/31

13.

State Street Corp

(3.1268%)

since

2025/06/30

14.

Novo A/S

(2.9144%)

since

2025/06/30

15.

Maverick Capital Ltd

(2.7638%)

since

2025/06/30

16.

Vanguard Total Stock Mkt Idx Inv

(2.7396%)

since

2025/07/31

17.

AllianceBernstein L.P.

(2.3806%)

since

2025/06/30

18.

Eversept Partners, LLC

(2.3298%)

since

2025/06/30

19.

Fidelity Advisor Biotechnology I

(2.1532%)

since

2025/07/31

20.

Baker Bros Advisors LP

(2.1361%)

since

2025/06/30

21.

Geode Capital Management, LLC

(2.1315%)

since

2025/06/30

22.

iShares Russell 2000 ETF

(2.0494%)

since

2025/08/31

23.

Fidelity Advisor Health Care I

(1.9222%)

since

2025/07/31

24.

Loomis, Sayles & Company LP

(1.639%)

since

2025/06/30

25.

Parkman Healthcare Partners LLC

(1.5905%)

since

2025/06/30

26.

US Small-Cap Growth II Equity Comp

(1.4814%)

since

2025/06/30

27.

T. Rowe Price New Horizons

(1.4227%)

since

2025/07/31

28.

Fidelity Small Cap Growth

(1.2913%)

since

2025/06/30

29.

FIAM Small Cap Core Composite

(1.2355%)

since

2025/03/31

30.

SPDR® S&P Biotech ETF

(1.1401%)

since

2025/08/31

31.

Fidelity Select Biotechnology

(1.1042%)

since

2025/07/31

32.

AB Small Cap Growth A

(1.0653%)

since

2025/07/31

33.

FIAM Small Cap Core CIT Cl B

(1.0496%)

since

2025/06/30

34.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9227%)

since

2025/07/31

35.

Loomis Sayles Small Cap Growth Instl

(0.901%)

since

2025/07/31

36.

Fidelity Series Small Cap Opps

(0.8693%)

since

2025/06/30

37.

Fidelity Small Cap Index

(0.8537%)

since

2025/06/30

38.

Pictet-Biotech P USD

(0.8372%)

since

2025/05/31

39.

Candriam Eqs L Biotech C USD Cap

(0.8117%)

since

2025/07/31

40.

Fidelity Stock Selector Small Cap

(0.7566%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.9558

Latest Release

Date

2025-09-30

EPS Actual

-0.34

EPS Estimate

-0.9532

EPS Difference

0.6132

Surprise Percent

64.3307%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.